Barclays targets Stryker stock at USD 375 after robotics deal

Published on 10/20/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker commits USD 400 million to CMR Surgical on October 12, 2026. Stryker stock costs EUR 266.90 on October 20, 2026, 0.34 percent above the Xetra close.

Robotics, results and valuation

Stryker committed USD 400 million to CMR Surgical on October 12, 2026.
Second-quarter revenue reached USD 6.59 billion, up 9.40 percent year over year.
Stryker stock trades at EUR 266.90 at 11:08 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.34 percent above the Xetra close of October 19, 2026.
Third-quarter results are scheduled for October 29, 2026.

Pop-Art-Comic zeigt Chirurgen mit robotergestütztem OP-System in leuchtenden Farben — Pop-Art-Comic-Illustration einer farbenfrohen Roboterchirurgie-Szene verbildlicht anschaulich das Geschäftsfeld von Stryker Corp. US8636671013 heute, Illustration mit AI erstellt.

Stryker Corporation (ISIN US8636671013) committed approximately USD 400 million to CMR Surgical on October 12, 2026, while Barclays set a USD 375.00 price target for Stryker stock. The deal adds soft-tissue robotics to Stryker's growth agenda ahead of its third-quarter results.

According to CMR Surgical on October 12, 2026, the investment gives Stryker an exclusive option to acquire all remaining CMR equity and exclusive U.S. sales rights for the Versius portfolio. Regulatory approvals and customary closing conditions still apply.

USD 400 million opens robotics route

The transaction gives Stryker a foothold in soft-tissue robotics without an immediate full acquisition. CMR will continue developing and commercializing Versius outside the United States, while Stryker contributes its hospital relationships and commercial reach.

That move follows a leadership change announced on October 6, 2026. Nasdaq reported that Spencer Stiles will become chief executive officer on January 1, 2027, while Kevin Lobo becomes executive chair.

What does the deal mean for growth?

Stryker's second-quarter revenue was USD 6.59 billion, up 9.40 percent from the same period a year earlier, according to MarketBeat. Adjusted earnings per share reached USD 3.69 against a USD 3.49 consensus estimate, giving investors a demanding test for the next quarter.

Stryker's chronology includes second-quarter results on July 30, 2026, the leadership succession announcement on October 6, 2026, and the CMR Surgical investment on October 12, 2026. The next two dates are third-quarter results on October 29, 2026, and the CEO transition on January 1, 2027.

Stock price and upcoming results

The current setup combines a new robotics option with a defined earnings date. Stryker's market capitalization is EUR 102.0 billion, and its 52-week range is EUR 210.60 to EUR 337.30 as of October 20, 2026.

Stryker stock was trading at EUR 266.90 at Lang & Schwarz on October 20, 2026, at 11:08 a.m. CEST, up 0.34 percent versus the Xetra close of October 19, 2026, at EUR 266.00. The further course of trading is shown by the continuously updated real-time quote of Stryker stock.